A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Single Ascending and Multiple Oral Doses of MB-110 and to Evaluate the Antiviral Activity in Hepatitis C Virus Infected Patients
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 11 Apr 2017
At a glance
- Drugs MB 110 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- Sponsors MICROBIO Group
- 04 Apr 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 04 Apr 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
- 04 Apr 2017 Planned initiation date changed from 1 Jan 2016 to 1 Dec 2017.